{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:47:54Z","timestamp":1794646074191,"version":"4.9.1"},"reference-count":66,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,5,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Monoclonal gammopathy of unknown significance (MGUS) and smoldering multiple myeloma (SMM) are asymptomatic plasma cell dyscrasias, with a propensity to progress to symptomatic MM. In recent years there have been improvements in risk stratification models (involving molecular markers) of both disorders, which have led to better understanding of the biology and probability of progression of MGUS and SMM. In the context of numerous molecular events and heterogeneous risk of progression, developing individualized risk profiles for patients with MGUS and SMM represents an ongoing challenge that has to be addressed by prospective clinical monitoring and extensive correlative science. In this review we discuss the current standard of care of patients with MGUS and SMM, the use of risk models, including flow cytometry and free-light chain analyses, for predicting risk of progression. Emerging evidence from molecular studies on MGUS and SMM, involving cytogenetics, gene-expression profiling, and microRNA as well as molecular imaging is described. Finally, future directions for improving individualized management of MGUS and SMM patients, as well as the potential for developing early treatment strategies designed to delay and prevent development of MM are discussed.<\/jats:p>","DOI":"10.1182\/blood-2011-01-270140","type":"journal-article","created":{"date-parts":[[2011,3,27]],"date-time":"2011-03-27T00:13:09Z","timestamp":1301184789000},"page":"5573-5581","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":167,"title":["Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies"],"prefix":"10.1182","volume":"117","author":[{"given":"Neha","family":"Korde","sequence":"first","affiliation":[{"name":"Medical Oncology Branch, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD;"},{"name":"Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigurdur Y.","family":"Kristinsson","sequence":"additional","affiliation":[{"name":"Hematology Center, Karolinska University Hospital and Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[{"name":"Medical Oncology Branch, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"18","key":"2019111710334706900_B1","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma.","volume":"351","author":"Kyle","year":"2004","journal-title":"N Engl J Med"},{"issue":"13","key":"2019111710334706900_B2","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance.","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111710334706900_B3","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111710334706900_B4","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1182\/blood-2005-08-3449","article-title":"Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States.","volume":"107","author":"Landgren","year":"2006","journal-title":"Blood"},{"issue":"12","key":"2019111710334706900_B5","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S0025-6196(11)61089-6","article-title":"Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana.","volume":"82","author":"Landgren","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"25","key":"2019111710334706900_B6","doi-asserted-by":"crossref","first-page":"6386","DOI":"10.1182\/blood-2009-02-203471","article-title":"Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study.","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2019111710334706900_B7","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2008-12-192575","article-title":"Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance.","volume":"114","author":"Vachon","year":"2009","journal-title":"Blood"},{"issue":"11","key":"2019111710334706900_B8","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3324\/haematol.2009.008979","article-title":"Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies.","volume":"94","author":"Kristinsson","year":"2009","journal-title":"Haematologica"},{"issue":"22","key":"2019111710334706900_B9","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"22","key":"2019111710334706900_B10","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients.","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"key":"2019111710334706900_B11","first-page":"211","article-title":"Studies on conditions associated with disturbed gamma globulin formation (gammopathies).","volume":"56","author":"Waldenstrom","year":"1960","journal-title":"Harvey Lect"},{"issue":"5","key":"2019111710334706900_B12","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0002-9343(78)90522-3","article-title":"Monoclonal gammopathy of undetermined significance: natural history in 241 cases.","volume":"64","author":"Kyle","year":"1978","journal-title":"Am J Med"},{"issue":"10","key":"2019111710334706900_B13","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4065\/mcp.2010.0520","article-title":"Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence.","volume":"85","author":"Rajkumar","year":"2010","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"2019111710334706900_B14","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance.","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111710334706900_B15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1053\/sonc.2003.50062","article-title":"Long-term follow-up of IgM monoclonal gammopathy of undetermined significance.","volume":"30","author":"Kyle","year":"2003","journal-title":"Semin Oncol"},{"issue":"9727","key":"2019111710334706900_B16","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","article-title":"Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.","volume":"375","author":"Dispenzieri","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"2019111710334706900_B17","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.","volume":"121","year":"2003","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111710334706900_B18","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"issue":"3","key":"2019111710334706900_B19","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2019111710334706900_B20","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"issue":"7","key":"2019111710334706900_B21","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.","volume":"110","author":"Perez-Persona","year":"2007","journal-title":"Blood"},{"issue":"12","key":"2019111710334706900_B22","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1182\/blood-2010-04-277566","article-title":"Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications.","volume":"116","author":"Bianchi","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2019111710334706900_B23","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma.","volume":"28","author":"Hillengass","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111710334706900_B24","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1182\/blood-2003-02-0493","article-title":"The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma.","volume":"102","author":"Fonseca","year":"2003","journal-title":"Blood"},{"issue":"2","key":"2019111710334706900_B25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.leu.2402797","article-title":"Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma.","volume":"17","author":"Debes-Marun","year":"2003","journal-title":"Leukemia"},{"issue":"6","key":"2019111710334706900_B26","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/sj.leu.2401041","article-title":"Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases.","volume":"12","author":"Smadja","year":"1998","journal-title":"Leukemia"},{"issue":"3","key":"2019111710334706900_B27","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/gcc.10275","article-title":"Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases.","volume":"38","author":"Smadja","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"2019111710334706900_B28","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/sj.leu.2403256","article-title":"Chromosomal abnormalities clustering in multiple myeloma reveals cytogenetic subgroups with nonrandom acquisition of chromosomal changes.","volume":"18","author":"Saez","year":"2004","journal-title":"Leukemia"},{"issue":"12","key":"2019111710334706900_B29","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"issue":"12","key":"2019111710334706900_B30","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3324\/haematol.2009.011064","article-title":"Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.","volume":"94","author":"Chiecchio","year":"2009","journal-title":"Haematologica"},{"issue":"4","key":"2019111710334706900_B31","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","article-title":"Genetics and cytogenetics of multiple myeloma: a workshop report.","volume":"64","author":"Fonseca","year":"2004","journal-title":"Cancer Res"},{"issue":"1","key":"2019111710334706900_B32","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2004-03-0833","article-title":"Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors.","volume":"105","author":"Rasmussen","year":"2005","journal-title":"Blood"},{"issue":"12","key":"2019111710334706900_B33","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1038\/leu.2008.142","article-title":"Clinical and biological significance of RAS mutations in multiple myeloma.","volume":"22","author":"Chng","year":"2008","journal-title":"Leukemia"},{"issue":"2","key":"2019111710334706900_B34","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2008.01.007","article-title":"AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies.","volume":"13","author":"Chesi","year":"2008","journal-title":"Cancer Cell"},{"issue":"4","key":"2019111710334706900_B35","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","article-title":"Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.","volume":"109","author":"Zhan","year":"2007","journal-title":"Blood"},{"issue":"7","key":"2019111710334706900_B36","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3324\/haematol.2008.004440","article-title":"Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case.","volume":"94","author":"Chiecchio","year":"2009","journal-title":"Haematologica"},{"issue":"21","key":"2019111710334706900_B37","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1001\/jama.2010.1713","article-title":"Multiple myeloma precursor disease.","volume":"304","author":"Landgren","year":"2010","journal-title":"JAMA"},{"issue":"4","key":"2019111710334706900_B38","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.beha.2007.08.004","article-title":"Genetic events in the pathogenesis of multiple myeloma.","volume":"20","author":"Chng","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"issue":"9","key":"2019111710334706900_B39","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/sj.leu.2404304","article-title":"Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma.","volume":"20","author":"Chiecchio","year":"2006","journal-title":"Leukemia"},{"issue":"2","key":"2019111710334706900_B40","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ccr.2007.07.004","article-title":"Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.","volume":"12","author":"Annunziata","year":"2007","journal-title":"Cancer Cell"},{"issue":"1","key":"2019111710334706900_B41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ydbio.2006.08.028","article-title":"micro-RNAs as oncogenes and tumor suppressors.","volume":"302","author":"Zhang","year":"2007","journal-title":"Dev Biol"},{"issue":"35","key":"2019111710334706900_B42","doi-asserted-by":"crossref","first-page":"12885","DOI":"10.1073\/pnas.0806202105","article-title":"MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis.","volume":"105","author":"Pichiorri","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2019111710334706900_B43","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/leu.2009.89","article-title":"International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma.","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"issue":"2","key":"2019111710334706900_B44","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0009-9260(67)80010-2","article-title":"The radiological demonstration of osseous metastases: experimental observations.","volume":"18","author":"Edelstyn","year":"1967","journal-title":"Clin Radiol"},{"issue":"2","key":"2019111710334706900_B45","first-page":"272","article-title":"Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET\/CT and comparison between 18F-fluoride PET and 18F-fluoride PET\/CT.","volume":"45","author":"Even-Sapir","year":"2004","journal-title":"J Nucl Med"},{"issue":"8","key":"2019111710334706900_B46","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood-2003-08-2946","article-title":"Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity.","volume":"103","author":"Asosingh","year":"2004","journal-title":"Blood"},{"issue":"9","key":"2019111710334706900_B47","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1158\/1078-0432.CCR-08-2310","article-title":"Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation.","volume":"15","author":"Hillengass","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2019111710334706900_B48","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","article-title":"Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I\u2013a randomized study. Myeloma Group of Western Sweden.","volume":"50","author":"Hjorth","year":"1993","journal-title":"Eur J Haematol"},{"issue":"8","key":"2019111710334706900_B49","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2008-06-164228","article-title":"Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"issue":"7","key":"2019111710334706900_B50","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/cncr.23783","article-title":"A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.","volume":"113","author":"Musto","year":"2008","journal-title":"Cancer"},{"issue":"22","key":"2019111710334706900_B51","article-title":"Multicenter, randomized, open-label, phase III trial of lenalidomide-dexamethasone (len\/dex) vs therapeutic abstention in smoldering multiple myeloma at high risk of progression to symptomatic MM: results of the first interim analysis [abstract].","volume":"114","author":"Mateos","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"2","key":"2019111710334706900_B52","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.leu.2405016","article-title":"Clinically relevant end points and new drug approvals for myeloma.","volume":"22","author":"Anderson","year":"2008","journal-title":"Leukemia"},{"key":"2019111710334706900_B53","doi-asserted-by":"crossref","article-title":"Maintenance treatment with lenalidomide after transplantation for MYELOMA: final analysis of the IFM 2005-02.","author":"Attal","DOI":"10.1182\/blood.V116.21.310.310"},{"issue":"4","key":"2019111710334706900_B54","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3816\/CLML.2010.n.053","article-title":"Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future.","volume":"10","author":"Waxman","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"2019111710334706900_B55","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1359\/JBMR.041131","article-title":"Fracture risk with multiple myeloma: a population-based study.","volume":"20","author":"Melton","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2019111710334706900_B56","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/sj.leu.2402183","article-title":"Thalidomide for previously untreated indolent or smoldering multiple myeloma.","volume":"15","author":"Rajkumar","year":"2001","journal-title":"Leukemia"},{"issue":"2","key":"2019111710334706900_B57","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4065\/84.2.114","article-title":"Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component.","volume":"84","author":"Lust","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"18","key":"2019111710334706900_B58","doi-asserted-by":"crossref","first-page":"5917","DOI":"10.1158\/1078-0432.CCR-08-2217","article-title":"The potential role of curcumin in patients with monoclonal gammopathy of undefined significance\u2013its effect on paraproteinemia and the urinary N-telopeptide of type I collagen bone turnover marker.","volume":"15","author":"Golombick","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2019111710334706900_B59","unstructured":"Kalaycio\n              ME\n            \n          \n          Celecoxib in preventing multiple myeloma in patients with monoclonal gammopathy or smoldering myeloma.\n          Accessed September 21, 2009\n          Bethesda, MD\n          US National Institutes of Health\n          \n            http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00099047?term=Smoldering+OR+Indolent&cond=Multiple+Myeloma&rank=5"},{"key":"2019111710334706900_B60","unstructured":"Mateos\n              MV\n            \n            \n              San Miguel\n              J\n            \n            \n              Blade\n              J\n            \n            \n              Lahuerta\n              JJ\n            \n          \n          QUIREDEX: revlimid (lenalidomide) and dexamethasone (ReDex) treatment versus observation in patients with smoldering multiple myeloma with high risk of progression.\n          2007\n          Accessed September 21, 2009\n          Bethesda, MD\n          US National Institutes of Health\n          \n            http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00480363?term=Smoldering+OR+Indolent&cond=Multiple+Myeloma&rank=3"},{"key":"2019111710334706900_B61","unstructured":"Ballester\n              OF\n            \n          \n          Omega 3 supplementation for the prevention of disease progression in early stage chronic lymphocytic leukemia (ES-CLL), monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).\n          2009\n          Accessed September 21, 2009\n          Bethesda, MD\n          US National Institutes of Health\n          \n            http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00899353?term=Smoldering+OR+Indolent&cond=Multiple+Myeloma&rank=7"},{"key":"2019111710334706900_B62","unstructured":"Zonder\n              JA\n            \n            \n              Shannon\n              K\n            \n          \n          Green tea extract in treating patients with monoclonal gammopathy of undetermined significance and\/or smoldering multiple myeloma.\n          2009\n          Accessed September 21, 2009\n          Bethesda, MD\n          US National Institutes of Health\n          \n            http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00942422?term=Smoldering+OR+Indolent&cond=Multiple+Myeloma&rank=6"},{"key":"2019111710334706900_B63","unstructured":"ClinicalTrialsDatabase\n          Lenalidomide or observation in treating patients with asymptomatic high-risk smoldering multiple myeloma; 2010.\n          Accessed November 21, 2010\n          \n            http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01169337?term=smoldering+myeloma&rank=6"},{"key":"2019111710334706900_B64","unstructured":"ClinicalTrialsDatabase\n          A phase II trial of IPH2101 (anti-KIR) in smoldering multiple myeloma (SMM); 2010.\n          Accessed November 21, 2010\n          \n            http:\/\/clinicaltrials.gov"},{"issue":"12","key":"2019111710334706900_B65","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.3109\/10428194.2010.525725","article-title":"Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma.","volume":"51","author":"Mailankody","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2019111710334706900_B66","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1586\/erm.10.31","article-title":"Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis.","volume":"10","author":"Balakumaran","year":"2010","journal-title":"Exp Rev Mol Diagn"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/117\/21\/5573\/1337921\/zh802111005573.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/117\/21\/5573\/1337921\/zh802111005573.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T15:34:21Z","timestamp":1574004861000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/117\/21\/5573\/21406\/Monoclonal-gammopathy-of-undetermined-significance"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,26]]},"references-count":66,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2011,5,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-01-270140","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,26]]}}}